Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era

Simon Mantha, MD MPH, Debra Goldman, MS, Sean M. Devlin, PhD, Ju-Whei Lee, PhD, Diana Zannino, BSc, MSc, Dan Douer, MD, Harry J Iland, MBBS FRACP FRCPA, Mark R. Litzow, MD, Eytan M. Stein, Frederick Appelbaum, MD, Richard A. Larson, Jacob M. Rowe, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 948.

https://doi.org/10.1182/blood.V124.21.948.948

Published: 2014

Journal Articles

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Marcello Rotta, MD, Barry Storer, PhD, Firoozeh Sahebi, MD, Judith A. Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Thoralf Lange, MD, Peter A. McSweeney, MD, Michael Pulsipher, MD, Parameswaran Hari, MD, MS, Richard Thomas Maziarz, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick Appelbaum, MD, William Bensinger, MD, Brenda Sandmaier, MD, PhD, Rainer Storb, MD, David G. Maloney, MD, PhD

Blood (2008) 112 (11): 1130.

https://doi.org/10.1182/blood.V112.11.1130.1130

Published: 2008

Journal Articles

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

John Gregory, MD, Haesook Kim, PhD, Todd Alonzo, MD, Rob Gerbing, PhD, Angela Ogden, MD, William Woods, MD, Howard Weinstein, MD, Lois Shepherd, MD, Charles Schiffer, MD, Frederick Appelbaum, MD, Cheryl Willman, MD, Peter Wiernik, MD, Jacob Rowe, MD, Martin Tallman, MD, James Feusner, MD

Blood (2005) 106 (11): 894.

https://doi.org/10.1182/blood.V106.11.894.894

Published: 2005

Journal Articles

Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study.

Steven M. Kornblau, MD, Deborah E. Banker, MD, Elizabeth Lemker, Zeev Estrov, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Farhad Ravandi-Kashani, MD, Michael Andreeff, MD, PhD, C. Ellen Jackson, Wenjing Chen, Stephen Petersdorf, MD, Elihu Estey, MD, Frederick Appelbaum, MD

Blood (2005) 106 (11): 405.

https://doi.org/10.1182/blood.V106.11.405.405

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study.

Email alerts

ASH Publications

American Society of Hematology

Update search

Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only